response scores than the non-irradiated sites. Statistically significant differences in the mean dermal response score were observed between tapinarof cream 1% irradiated and tapinarof cream 1% non-irradiated sites (P=0.0014), as well as between vehicle irradiated and vehicle non-irradiated sites (P=0.0044).
Additional Safety Measures
A low incidence of AEs was reported across the 4 trials (Table 5). All AEs occurred in the photoallergy trial and none was considered related to tapinarof cream 1%. Four participants (6.9%) in the photoallergy trial experienced 5 treatmentemergent AEs (TEAEs); 2 were mild in severity (urinary tract infection and headache), 1 was moderate (nausea), and 2 were severe (nephrolithiasis and ligament sprain). Two participants discontinued the study due to AEs.
